The QualityStocks Daily Wednesday, August 23rd, 2023

Today's Top 3 Investment Newsletters

MarketClub Analysis(VCIG) $6.9000 +83.80%

Green Car Stocks(MULN) $0.8000 +68.07%

Stocks to Buy Now(KAVL) $0.5961 +35.48%

The QualityStocks Daily Stock List

Pieris Pharmaceuticals (PIRS)

Wall Street Resources, MarketClub Analysis, QualityStocks, Streetwise Reports, TraderPower, BUYINS.NET, StreetInsider, MarketBeat, StockMarketWatch, TradersPro, InvestorPlace, Barchart, Schaeffer's, Zacks, The Street, Promotion Stock Secrets, AllPennyStocks, Profit Confidential,, StockOodles, The Online Investor, Investopedia, Market Report and Trades Of The Day reported earlier on Pieris Pharmaceuticals (PIRS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Pieris Pharmaceuticals Inc. (NASDAQ: PIRS) (FRA: P16) is a clinical-stage biopharmaceutical firm that is engaged in the discovery and development of protein-based drugs in the U.S.

The firm has its headquarters in Boston, Massachusetts and was founded in 2001 by Arne Skerra. It operates in the healthcare sector under the biotech and pharma sub-industry. It serves consumers across the globe and is a part of the scientific research and development services industry.

The enterprise is party to a clinical trial supply and collaboration agreement with Eli Lilly and Company. In addition, it is also party to license agreements with Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd, Enumeral Biomedical Holdings Inc. and the Technical University of Munich, as well as collaboration and license agreements with Seagen Inc., AstraZeneca AB, Institut de Recherches Internationales Servier and Les Laboratoires Servier.

The company’s product pipeline is made up of a preclinical-stage program that addresses immune-oncology ailments called PRS-352; an anticalin-antibody fusion protein that targets PD-L1 and 4-1BB for immune-oncology ailments dubbed PRS-344; an immune-oncology program indicated for treating HER2-expressing solid tumors and an anticalin-based drug candidate dubbed AZD1402/PRS-060 that targets IL-4Ra for treating asthma and other inflammatory ailments. It produces differentiated drugs that help patients suffering from anemia, asthma, severe cancer and other medical conditions.

The firm recently entered into a research and development agreement with Genentech Inc. for ophthalmology and respiratory treatments. This major move will allow Pieris to bring new drugs through early clinical and preclinical development while Genentech takes over commercialization and development. This agreement encourages investments into the firm, which could boost growth and increase the firm’s revenue.

Pieris Pharmaceuticals (PIRS), closed Wednesday's trading session at $0.439, up 19.6838%, on 9,783,260 volume. The average volume for the last 3 months is 1.023M and the stock's 52-week low/high is $0.1616/$1.97.

Matinas BioPharma Holdings (MTNB)

QualityStocks, MarketBeat, StockMarketWatch, TraderPower, BUYINS.NET, InvestorPlace,, Stock News Now, Zacks, StreetInsider, The Online Investor, SmallCapVoice, Schaeffer's, Tiny Gems, Trades Of The Day, Wall Street Mover, Wealth Insider Alert, FreeRealTime and Stock News reported earlier on Matinas BioPharma Holdings (MTNB), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) (FRA: 6LG) is a clinical-stage biopharmaceutical firm that is focused on the discovery and development of treatments for various indications.

The firm has its headquarters in Bedminster, New Jersey and was incorporated in May 2013 by Jerome D. Jabbour. It operates as part of the pharmaceutical and medicine industry, in the biotech and pharma sub-industry, under the health care sector. The firm has three companies in its corporate family and serves consumers in the United States.

The company is focused on enabling the delivery of life-changing medications using its lipid nano-crystals platform technology. Its technology encapsulates proteins, peptides, vaccines, oligonucleotides, small molecule drugs and other medications, making them orally bioavailable, less toxic, more tolerable and safer. The company is party to a feasibility collaboration with Genentech Inc., which entails the development of oral formulations; and research collaborations with ViiV Healthcare for the development and evaluation of formulations for antiviral drugs, as well as NINDS (National Institute of Neurological Disorders and Stroke), which entails the development of new treatments for HIV.

The enterprise's product pipeline is made up of an orally administered formulation dubbed MAT2501 which has concluded phase 1 clinical trials evaluating its effectiveness in treating intracellular bacterial infections and different types of multidrug-resistant gram negative infections and multidrug-resistant bacteria, which includes non-tuberculosis mycobacterium infections. It also develops an oral amphotericin B formulation known as MAT2203 which has been developed to prevent invasive fungal infections. The formulation is currently in phase 2 clinical trials.

The company recently announced positive safety and effectiveness data for its MAT2203 phase 2 trial. The formulation has been found to be effective in clearing fungal organisms. The success and eventual approval of the drug will be beneficial to patients and help bring in more investors into the company.

Matinas BioPharma Holdings (MTNB), closed Wednesday's trading session at $0.189, up 17.9775%, on 1,050,294 volume. The average volume for the last 3 months is 242,776 and the stock's 52-week low/high is $0.1103/$0.89.

Corvus Pharmaceuticals (CRVS)

MarketClub Analysis, MarketBeat, StreetInsider, StockMarketWatch, Schaeffer's, QualityStocks, Zacks, BUYINS.NET, TraderPower, TopPennyStockMovers, Trades Of The Day, TradersPro, The Street, PoliticsAndMyPortfolio and Penny Stock reported earlier on Corvus Pharmaceuticals (CRVS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Corvus Pharmaceuticals Inc. (NASDAQ: CRVS) (FRA: C17) is a clinical stage biopharmaceutical firm that is focused on developing and commercializing immune-oncology therapies.

The firm has its headquarters in Burlingame, California and was incorporated in 2014, on January 27th by Joseph J. Buggy, Peter A. Thompson and Richard A. Miller. It operates as part of the pharmaceutical and medicine manufacturing industry, under the health care sector.

The company is party to a strategic collaboration with Angel Pharmaceuticals Ltd, which entails developing its pipeline of investigational medicines. The company serves consumers in the United States.

The enterprise’s product pipeline comprises of an oral small molecule A2A receptor antagonist dubbed CPI-444, which is undergoing a phase 2 clinical trial for adenosine; a covalent ITK inhibitor known as CPI-818, which is in a phase 1 clinical trial evaluating its effectiveness in treating individuals with malignant T-cell lymphomas; and an anti-CD73 monoclonal antibody dubbed CPI-006, which is undergoing a phase 3 trial for coronavirus as well as a phase 1 trial that activates different immune cells and inhibits adenosine production. The enterprise’s pre-clinical stage products include an adenosine A2B receptor antagonist dubbed CPI-935, which is indicated for fibrosis prevention; and an antibody known as CPI-182, which has been designed to block myeloid derived suppressor cells as well as neutrophil migration and function.

An Investigational New Drug application submitted by the company’s partner Angel Pharmaceuticals for their CPI-818 formulation has been accepted by the China National Medical Products Administration Center for Drug Evaluation. The success and approval of the formulation for use in treating relapsed/refractory T-cell lymphomas will benefit patients as well as bring in more revenues and investors into both companies.

Corvus Pharmaceuticals (CRVS), closed Wednesday's trading session at $2.32, up 11.0048%, on 242,776 volume. The average volume for the last 3 months is 2.17M and the stock's 52-week low/high is $0.607/$4.19.

The Beachbody Company (BODY)

SmarTrend Newsletters, The Street, Gryphon Digest, MarketBeat, StreetInsider, QualityStocks, DrStockPick, Hit and Run Candle Sticks, Barchart, PennyOmega, TradingMarkets, StreetAuthority Daily, Schaeffer's, CRWEFinance, CRWEWallStreet, Dividend Opportunities, TheStockAdvisor, Dynamic Wealth Report, Millennium-Traders, Street Insider, PennyToBuck, InvestorPlace, InvestorTrendz, Louis Navellier, StockHotTips, Planet MicroCap and FNNO Newsletters reported earlier on The Beachbody Company (BODY), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The Beachbody Company Inc. (NYSE: BODY) is a holding firm that operates a health and wellness platform which offers stress-reducing, nutrition and fitness programs.

The firm has its headquarters in Santa Monica, California and was incorporated in 1998 by Jon Congdon and Carl Daikeler. The firm serves consumers around the globe.

The company operates through two segments and has more than two decades of experience creating innovative content. It has developed a fitness digital streaming platform with a content library that contains more than 2300 streaming workouts and roughly 80 complete workout programs.

The enterprise operates various digital platforms, which include a digital subscription platform known as Beachbody on Demand, which offers access to the company’s library of on-demand and live nutrition and fitness content. Its other digital streaming platform; Openfit, offers digital wellness and fitness resources. It also operates its connected fitness brand, known as Myx fitness. The enterprise’s digital subscriptions include free-to-pay and paid subscriptions. In addition to this, it provides nutritional products, which include Collagen, Bevvy- its low sugar protein bars, its Beachbody performance supplements, which contain a pre-workout, post-workout and recovery recharge products; and a once daily premium nutrition shake known as Shakeology. The enterprise’s other brands include Beachbody Performance and Ladder.

The company recently launched BODi, its live interactive premium subscription tier, which brings the energy and experience of a fitness class into the homes of Beachbody members. This product will not only extend the company’s consumer reach but also encourage more investments into the company, which will have a positive influence on the company’s growth.

The Beachbody Company (BODY), closed Wednesday's trading session at $0.43, up 20.6171%, on 2,172,994 volume. The average volume for the last 3 months is 17,653 and the stock's 52-week low/high is $0.32/$1.43.

SinglePoint (SING)

QualityStocks, NetworkNewsWire, StocksToBuyNow, CannabisNewsWire, CryptoCurrencyWire, SmallCapRelations,, MoneyTV, SeriousTraders, PennyStocks24, Xtremepicks, CFN Media Group, RedChip, MarketBeat, Pumps and Dumps, MyBestStockAlerts, Top Stock Tips, Investor News Source, OurHotStockPicks, Stock Tips Network, Promotion Stock Secrets, Journal Transcript, SmallCapVoice, MassiveStockProfits, The FrontPageStocks, First Penny Picks, Shiznit Stocks, SmallCapSociety, Jet-Life Penny Stocks, Penny Stock General, Red Chip, Stock Commander, Wallstreetbuzz, The Street,, Equity Observer, Kiplinger Today, CBDWire, Elite Stock Alerts, Daily Trade Alert, Fast Money Alerts,, Wallstreetlivechat, Tiny Gems, StockRockandRoll, Stockgoodies, Stock Shock and Awe, Penny Stocks On Steroids, POSstocks, MomentumOTC, PennyStockLocks, Brilliant Penny Stocks, Penny Stock 101, Penny Dreamers, Penny Champions, OtcWizard and PremiereStockAlerts reported earlier on SinglePoint (SING), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

SinglePoint Inc. (OTCQB: SING) is a renewable energy and sustainable solutions firm engaged in the provision of renewable energy solutions and energy-efficient applications in the United States.

The firm has its headquarters in Phoenix, Arizona and was incorporated in 2007, on October 15th by Gregory P. Lambrecht. It operates as part of the solar industry, under the technology sector. The firm serves consumers in America, with a focus on those in the state of Arizona.

The company is focused on building the biggest network of renewable energy solutions and modernizing the traditional solar and energy storage model. Its subsidiaries include SinglePoint Direct Solar LLC (Direct Solar America) and EnergyWyze LLC (EnergyWyze).

The enterprise provides solar and air purification services through its Boston Solar Company LLC and Box Pure Air LLC subsidiaries; and solar installation and brokerage services. It also supplies hydroponic supplies and nutrients to commercial and individual farmers, as well as nutrients, lights, HVAC systems, and other products to individuals that are interested in horticulture; operates as an online store; and provides automotive technology solutions for vehicle repairs. In addition to this, the enterprise offers digital and direct marketing services focused on customer lead generation in the solar energy industry. Further, it provides solar, battery backup, and electric vehicle chargers to homeowners and commercial business.

The company, whose latest financial results show significant increases in its revenues, remains focused on exploring future growth opportunities in EV charging, air purification, and solar as a subscription services.

SinglePoint (SING), closed Wednesday's trading session at $1.63, up 15.6028%, on 17,653 volume. The average volume for the last 3 months is 65,024 and the stock's 52-week low/high is $0.010228/$8.316.

Phenom Resources (PHNMF)

We reported earlier on Phenom Resources (PHNMF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Phenom Resources Corp (OTCQX: PHNMF) (CVE: PHNM) FRA: 1PY0) is a company focused on acquiring, exploring for, evaluating and developing gold, copper and vanadium mineral properties in the United States and Canada.

The firm has its headquarters in Vancouver, Canada and was incorporated in 2006, on June 23rd. Prior to its name change in July 2021, the firm was known as First Vanadium Corp. It operates as part of the gold industry, under the basic materials sector. The firm serves consumers around the globe.

The company holds 100% interest in the Carlin gold-vanadium project, which comprises of about 150 unpatented mining claims and 80 acres of fee-simple land that covers approximately 2,608 acres located in North-Central Nevada in Elko County, seven miles south of Carlin; and the South Carlin Section 22 property also in Elko County, consisting of 36 unpatented mining claims located one mile north of the Carlin Gold-Vanadium Property on the Carlin Gold Trend of Nevada. The company also owns interests in the West Jerome property, located in the copper-rich district of Arizona, near the Town of Jerome in Central Arizona. In addition to this, it holds an option to acquire a 100% interest in the SMOKE Property.

The firm recently signed a Definitive Offtake Agreement with private Japanese battery companyMK Plus Company Limited. This move affords it a 5% equity interest in the firm, which is advancing its revolutionary fast charging low-cost vanadium solid-state battery (VSB) business worldwide. This may, in turn, help generate additional value for its shareholders while also extending the firm’s consumer reach.

Phenom Resources (PHNMF), closed Wednesday's trading session at $0.1858, up 3.2796%, on 65,024 volume. The average volume for the last 3 months is 60,910 and the stock's 52-week low/high is $0.1719/$0.4009.

Boardwalktech Software (BWLKF)

We reported earlier on Boardwalktech Software (BWLKF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Boardwalktech Software Corp. (OTCQB: BWLKF) (CVE: BWLK) is a company focused on designing and licensing enterprise Software-as-a-Service solutions globally.

The firm has its headquarters in Cupertino, California and was incorporated in 1996, on April 4th. It operates as part of the software-application industry, under the technology sector. The firm serves consumers around the globe.

The enterprise’s solutions resolve two enterprise business problems, such as connecting multiple users in the enterprise value chain to improve planning and results and the alignment of data from various enterprise systems of record used in planning and information exchange processes. Its offerings include the Boardwalk Digital Ledger platform for building and maintaining applications with multiple internal or external users working in Excel, a web form, or mobile environment as the user interface; Boardwalk Cloud for Excel that allows working in excel files on the desktop while the data is managed in the cloud enabling users to collaborate, share, and see the history; Radius that offers predictive analytics for structured and unstructured enterprise information; Unity Central for document and knowledge management; Velocity, a low-code platform to mitigate Excel risk in the enterprise; and excel-based planning applications. The enterprise serves the CPG, High Tech, Insurance, Financial Services, Manufacturing, Retail, Apparel, and government industries. Its revenue is generated from two primary sources; professional services and software subscriptions and services.

The company, whose latest financial results show increases in its revenues, remains committed to capitalizing on opportunities that will bolster its overall growth.

Boardwalktech Software (BWLKF), closed Wednesday's trading session at $0.3814, up 0.368421%, on 60,910 volume. The average volume for the last 3 months is 167 and the stock's 52-week low/high is $0.37/$0.70753.

Interra Copper (IMIMF)

We reported earlier on Interra Copper (IMIMF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Interra Copper Corp (OTCQB: IMIMF) (CNSX: IMCX) (FRA: 3MX) is a junior mineral exploration firm that acquires, explores for and evaluates natural resource properties in Canada.

The firm has its headquarters in Vancouver, Canada and was incorporated in 2018, on August 30th. Prior to its name change in May 2021, the firm was known as IMC International Mining Corp. It operates as part of the other industrial metals and mining industry, under the basic materials sector. The firm serves consumers in Canada.

The enterprise holds interest in the Thane gold, copper and silver property, which covers an area of 50,904 acres (roughly 206km2) and is located in Quesnel Terrane of northcentral British Columbia. The Thane property is predominantly underlain by intrusive rocks of the Hogem Plutonic Suite. In addition, it holds an option agreement to acquire interest in the Chuck Creek property, which covers an area of 8,293 acres (about 33.57km2) situated in central British Columbia.The property is located within the Eagle Bay Assemblage of rocks and is surrounded on all sides by Taseko Mines’ Yellowhead property, which hosts a copper-gold volcanogenic sulfide deposit. The enterprise’s subsidiaries include Canadian Mining of Arizona Inc. and Thane Minerals Inc.

The company, which recently welcomed new members to its Board of Directors, remains focused on advancing its exploration efforts, charting its course for growth and building value for its shareholders.

Interra Copper (IMIMF), closed Wednesday's trading session at $0.21695, even for the day. The average volume for the last 3 months is 7 and the stock's 52-week low/high is $0.1664/$0.66.

Irwin Naturals (IWINF)

MarketBeat and TipRanks reported earlier on Irwin Naturals (IWINF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Irwin Naturals Inc. (OTCQB: IWINF) (CNSX: IWIN) (FRA: 97X) is a nutraceutical firm focused on developing and distributing vitamins and other health supplements in Canada and the United States.

The firm has its headquarters in Los Angeles, California. Prior to its name change, the firm was known as Datinvest International Limited. It operates as part of the pharmaceutical retailers industry, under the healthcare sector. The firm serves consumers around the globe, with a focus on those in the United States.

The company intends to heal the world through plant medicine. Its full range of Vitamin, CBD, and supplements features over 100 products, created to address mood and brain function, better sleep, sports performance, sexual health, immune support, weight management, women's health and men's health. The company's ketamine clinic, Emergence, is an infusion clinic that offers intravenous (IV) ketamine for the treatment of depression, post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), anxiety, bipolar disorder, migraines, and multiple chronic pain conditions like fibromyalgia, complex regional pain syndrome (CRPS) and reflex sympathetic dystrophy (RSD).

The enterprise offers a range of products, including CBD oils, topicals, gummies, soft gels, CBD creams, balms and roll-ons, vitamins and supplements, among other products. It sells its products through health food stores and mass market retailers, as well as through e-commerce retailers. The enterprise offers its products under the Irwin Naturals and Nature's Secret brands. Its portfolio of herbal products is available in more than 100,000 retail doors across North America.

The company, which recently entered into a licensing and supply agreement with the Hive Laboratory LLC, remains focused on better meeting consumer needs through the launch of new products and expanding its brand to products with THC.

Irwin Naturals (IWINF), closed Wednesday's trading session at $1.07, even for the day. The average volume for the last 3 months is 36,341 and the stock's 52-week low/high is $0.80/$3.50.

Mushrooms Inc. (MSRM)

We reported earlier on Mushrooms Inc. (MSRM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Mushrooms Inc. (OTC: MSRM) today announced its newly formed business development team, strategically assembled to harness the momentum generated by the company’s new technology and Innovation lab development. The team is comprised of accomplished professionals with diverse backgrounds and poised to drive Mushrooms Inc. into a new era of innovation and growth. “This enhanced business development team represents a pivotal milestone for Mushrooms Inc.,” said Donald Steinberg, board director of Mushrooms Inc. “As we make strides in the mushroom sector, our team’s collective experience and expertise provide a robust foundation for innovation and growth.”

To view the full press release, visit

About Mushrooms Inc.

Mushrooms is a publicly traded company on the OTC Markets with the stock symbol MSRM. The vision for the company is to support the growth of the mushroom industry through collaboration, innovation and development. Creating and supporting environmentally beneficial product innovation is at the heart of Mushrooms. Its current focus is on the industrial application of mycelium for the creation of carbon-neutral products for the building and health care industries as well as creating supplements based on the proven health benefits of mushrooms. Research and development is the path to achieving great innovation, and the pioneers are the ones the company looks to for fortitude and enduring dedication to the world of mycology. The working relationships it fosters will result in scientifically proven products that advance the health of body, mind and environment. For more information about the company, visit

Mushrooms Inc. (MSRM), closed Wednesday's trading session at $0.043, off by 6.5217%, on 36,411 volume. The average volume for the last 3 months is 29.615M and the stock's 52-week low/high is $0.015/$0.10.

NIO Inc. (NIO)

Green Car Stocks, InvestorPlace, Schaeffer's, MarketClub Analysis, The Street, MarketBeat, StocksEarning, Daily Trade Alert, Trades Of The Day, Kiplinger Today, The Online Investor, QualityStocks, INO Market Report, Zacks, StockEarnings, Early Bird, StreetInsider, StockMarketWatch, BUYINS.NET, Cabot Wealth, Wealth Insider Alert, The Wealth Report, CNBC Breaking News, InvestorsUnderground, Money Wealth Matters, Daily Wealth, GreenCarStocks, wyatt research newsletter, FreeRealTime, TradersPro, Investopedia, Green Energy Stocks, CRWEWallStreet, Energy and Capital, InvestorIntel, Investors Alley, InvestorsObserver Team, MarketClub, Louis Navellier, TopPennyStockMovers, AllPennyStocks, Wealth Daily, Smartmoneytrading, Stock Market Watch, The Night Owl, TipRanks, Top Pros' Top Picks, Top Pros’ Top Picks and Jim Cramer reported earlier on NIO Inc. (NIO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The average electric vehicle battery is designed to last 15 to 20 years before moving on to secondary applications. Still, it can reach its end of life earlier or later depending on EV driver habits. If you are looking to transition to an electric vehicle for the first time, you are likely curious about how you could maximize EV battery range and longevity.

Since buying a vehicle is the second largest purchase most Americans will make in their lives, maximizing the battery’s longevity will be key to minimizing vehicle-associated costs. Fortunately, electric vehicle manufacturers themselves are incentivized to design durable and long-lasting EV batteries.

EV manufacturers are also providing warranties that guarantee an average of at least 70% of the battery’s original capacity after around 100,000 miles or eight years. Additionally, taking care of an EV battery is relatively simple. Most new EV models come equipped with state-of-charge and intelligent temperature management to guide drivers on the most optimal charging levels.

EV drivers can also practice responsible fast-charging practices to avoid damaging their battery packs prematurely. With the addition of some basic battery-management science, drivers can leverage in-built vehicle technology and intelligent charging practices to maximize the longevity of their EV batteries.

This includes understanding the effect of extreme temperatures on EV battery packs. Hot temperatures limit your EV battery’s overall range and increase the risk of overheating while cold temperatures hamper the battery’s ability to store and release electricity. Cold temperatures also make batteries less efficient because they charge slower and have to expend more energy keeping the battery and vehicle interior warm.

Temperature extremes can also damage your EV battery over time and permanently limit its maximum capacity as well as its life expectancy. In-built technologies, including coolant lines and optimal temperature systems, ensure that EV batteries remain in the optimal ranges. Parking your electric car in the shade during hot days can protect it from the perils of extreme heat.

During cold weather, you can also prewarm your battery and the vehicle interior while the EV is still plugged in to reduce energy waste on heating. Avoid charging your EV to 100% and letting it run to 0% to prevent damaging the battery. Most EVs are equipped with technology for maintaining a healthy state of charge.

Finally, you will also want to avoid regularly fast charging your EV battery. While high-powered fast charging can be quite convenient, it causes an accumulation of lithium ions on the anode and results in a phenomenon called ion plating. Charging your EV overnight using private home chargers or over several hours using Level 2 chargers is the best way to maintain your EV battery’s performance and range over time.

As battery technology improves, the public is likely to embrace EVs more, and manufacturers such as NIO Inc. (NYSE: NIO) are likely to see their sales accelerating as the years go by.

NIO Inc. (NIO), closed Wednesday's trading session at $10.84, up 0.463392%, on 30,404,955 volume. The average volume for the last 3 months is 4.012M and the stock's 52-week low/high is $7.00/$22.74.

Bit Digital Inc. (BTBT)

QualityStocks, StocksEarning, MarketClub Analysis, Schaeffer's, TradersPro, InvestorPlace, StockEarnings, MarketBeat, InvestorsUnderground, Daily Trade Alert and CryptoCurrencyWire reported earlier on Bit Digital Inc. (BTBT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

On Aug. 18, 2023, at approximately 9:35 p.m. UTC, the value of Bitcoin experienced an abrupt drop of more than 8% within a mere 10-minute timeframe. This unexpected plunge had a domino effect on the broader cryptocurrency market, leaving those within the crypto community puzzled and perplexed.

While the precise catalyst behind this sudden market turbulence remains elusive, a variety of theories have been put forth by crypto market analysts in their discussions with Cointelegraph.

The influence of SpaceX

Josh Gilbert, a market analyst from eToro, attributed the downturn to a report indicating that SpaceX might have sold off a substantial portion, or possibly all, of its $373 million worth of Bitcoin holdings. This information stemmed from an article published by the Wall Street Journal on Aug. 17, 2023.

“Whenever a prominent industry player like Elon Musk is seen divesting from Bitcoin, it inevitably exerts downward pressure on its price,” the article noted.

This explanation aligns the sharp price decline with approximately two and a half hours following the publication of the aforementioned report.

Apprehensions regarding interest rates

Gilbert also introduced another perspective centered around the swift change in market sentiment attributed to the prevailing expectations of future interest rate hikes by the Fed.

“In light of the recent weaknesses across global markets, particularly in high-risk assets, coupled with the anticipation of sustained higher interest rates, the conditions were ripe for a corrective retreat,” explained Gilbert. “Bitcoin has grappled with limited upward momentum over the last month, confined within a tight price range of $29k to $30k, and the absence of favorable news only exacerbated the sell-off.”

Influences of government bond yields

CMC Markets market analyst Tina Teng provided an alternative perspective, citing the recent rise in government bond yields as the underlying factor contributing to the sell-off. Teng posited that an increase in bond yields typically indicates reduced liquidity within the broader market.

Furthermore, Teng dismissed the notion that the Evergrande crisis was a major catalyst for the Bitcoin price drop, asserting that its influence was mainly on investor sentiment towards the Chinese economy.

Persistent risk from the Chinese yuan

While Teng downplayed the impact of the Evergrande crisis, Markus Thielen, head of research at Matrixport, emphasized the potential influence of a devaluation of the Chinese yuan in prompting the sell-off. “The most significant macro risk involves the potential devaluation of the Chinese Yuan, which is presently trading at its weakest level since 2007,” he said.

Thielen recounted the historical context of the Chinese yuan’s devaluation in August 2015, during which Bitcoin prices experienced a 23% decline over the subsequent two weeks, followed by a notable rally later in the year.

Role of substantial sell-offs by major players

Among the myriad potential causes, TheFlowHorse, a pseudonymous derivatives trader, posited that the sudden downward movement could have been triggered by a significant sell-off by a single prominent actor, subsequently amplifying the pressure on derivatives.

“This wasn’t just a spontaneous cascade,” the trader noted. “A substantial player initiated a purposeful sell-off that set the events into motion. The spot trading volume was minuscule compared to the perpetual contracts.”

Data from Coinglass revealed the liquidation of over $427 million worth of Bitcoin in a four-hour period. Over the past 24 hours, long-position traders had witnessed liquidations exceeding $822 million; these positions speculated on the upward movement of cryptocurrency prices.

Categorizing many of the explanations offered as “speculative conjecture,” TheFlowHorse proposed an intriguing possibility: that an Ethereum Futures ETF’s potential approval by the SEC, announced shortly after the market drop, might have prompted a sizeable fund to offload their Bitcoin holdings, triggering a cascade of Ethereum purchases.

In the aftermath of the crash, Bitcoin exhibited a slight recovery, gaining 1.2% over a two-hour span, according to TradingView data. The positive price movement appears to have been influenced by reports indicating that the SEC might endorse an Ethereum Futures ETF product as early as October.

Regardless of the actual reason for that sudden price slump, one can be sure that crypto industry actors such as Bit Digital Inc. (NASDAQ: BTBT) now have their radars up to sniff out such future price movements in order to protect their holdings.

Bit Digital Inc. (BTBT), closed Wednesday's trading session at $2.63, up 8.6777%, on 4,016,207 volume. The average volume for the last 3 months is 57,444 and the stock's 52-week low/high is $0.5301/$4.795.

The QualityStocks Company Corner

Arizona Metals Corp. (TSX: AMC) (OTCQX: AZMCF)

The QualityStocks Daily Newsletter would like to spotlight Arizona Metals Corp. (TSX: AMC) (OTCQX: AZMCF).

Copper prices have fallen for the past several months amid a global energy crisis, worsening cost of living crisis and increasing geopolitical tension. Because copper's performance is traditionally associated with broader economic metrics, reducing copper prices have increased fears of a global economic slowdown. Prices for the red metal have trended downward partly due to reduced demand, particularly from major copper importer China, and disappointing import and export data from the Asian nation. A sharp drop in global demand caused by worsening economic conditions in Europe and slowed economic recovery in manufacturing giant China also caused prices to drop significantly as supply outpaced demand for the red metal. While most of the world removed coronavirus-related lockdowns in 2022, China doubled down on its strict anti-COVID policies and shut down large swathes of the country to maintain zero infection rates. As China plays a key role in the global economy, particularly in regards to manufacturing, shutdown orders caused copper suppliers to lose demand for several months as factories across China either slowed down or halted their operations. The existing stockpiles of copper at this time are unlikely to deter exploration companies such as Arizona Metals Corp. (TSX: AMC) (OTCQX: AZMCF) since future demand is likely to be high as greener forms of energy, including solar and wind energy, grow in prominence around the world.

Arizona Metals Corp. (TSX: AMC) (OTCQX: AZMCF) is a mineral exploration company engaged in advancing precious and base metal deposits in the state of Arizona. Its flagship copper-gold-zinc-silver asset is the Kay Mine Project, located in Yavapai County. The company also owns Sugarloaf Peak gold project in La Paz County.

The company in October 2022 received permit approval from the Bureau of Land Management (BLM) for two new drill pads, located approximately 1,200 meters west of the Kay Mine Deposit. These new pads will allow for testing of the company’s Western Target, while also allowing for drilling of additional coincident anomalies located between the Central and Western Targets. Construction of the drill road for the Central Target (located 500 meters west of the Kay Mine Deposit) is currently underway, with drilling expected to begin in November 2022. Road construction for the Western Target will begin upon confirmation of BLM acceptance of the company’s posted bond, with drilling expected to commence in Q1 2023.

The company is fully funded, with $60 million in cash as of June 30, 2022, to complete the remaining 18,000 meters planned for the Phase 2 program at Kay, as well as an additional 76,000 meters in the Phase 3 program (budgeted at $27 million), which will be used to test the numerous parallel targets heading west of the Kay Deposit, as well as the northern and southern extensions of the Kay Deposit.

Arizona Metals Corp. is based in Toronto, Canada.


Arizona Metals Corp. owns 100% of the Kay Mine property in Yavapai County, which is located on a combination of patented and BLM claims totaling 1,300 acres that are not subject to any royalties. An historic estimate by Exxon Minerals in 1982 reported a “proven and probable reserve of 6.4 million short tons at a grade of 2.2% copper, 2.8 grams per ton gold, 3.03% zinc, and 55 grams per ton silver.” The historic estimate has not been verified as a current mineral resource. None of the key assumptions, parameters, and methods used to prepare the historic estimate were reported by Exxon, and no resource categories were used. Significant data compilation, re-drilling and data verification may be required by a “qualified person” (as defined in National Instrument 43-101 – Standards of Disclosure for Mineral Projects) before the historic estimate can be verified and upgraded to be a current mineral resource. A qualified person has not done sufficient work to classify it as a current mineral resource, and Arizona Metals is not treating the historic estimate as a current mineral resource.

The company also owns 100% of the Sugarloaf Peak Property in La Paz County, which is located on 4,400 acres of BLM claims. Sugarloaf is a heap-leach, open-pit target and has a historic estimate of “100 million tons containing 1.5 million ounces (of) gold” at a grade of 0.5 grams per ton. The historic estimate at the Sugarloaf Peak Property was reported by Westworld Resources in 1983. The historic estimate has not been verified as a current mineral resource. None of the key assumptions, parameters, and methods used to prepare the historic estimate were reported, and no resource categories were used. Significant data compilation, re-drilling and data verification may be required by a qualified person before the historic estimate can be verified and upgraded to a current mineral resource. A qualified person has not done sufficient work to classify it as a current mineral resource, and Arizona Metals is not treating the historic estimate as a current mineral resource.

Market Opportunity

The World Gold Council, an industry association representing gold producers with hundreds of mining operations in nearly 50 countries around the world, reports that global demand for gold during the first six months of 2022 was 2,189 tons, a 12% increase in demand over the same period in 2021. Demand came primarily from gold bar and coin investors, jewelry consumers, central bank purchases to bolster currency reserves and technology manufacturing.

The average price per ounce for the period was $1,871, marking a 1% year-over-year increase. The council reported gold mine production for the period was up 3% over 2021 at 1,764 tons. For the remainder of 2022 and into 2023, the council projects flat gold demand with possible slight increases in gold mine production. The council notes that unpredictable geopolitical factors, the Ukraine war for example, and likelihood of global economic slowdown could have significant near-term impact on gold demand and prices.

Management Team

Marc Pais is President and CEO of Arizona Metals. He previously founded and served as President of Telegraph Gold (listed as Castle Mountain Mining), which was acquired by Equinox Gold, a TSX-listed mining company. He has seven years of experience as a Mining Analyst, with a focus on precious metals development companies. He holds a B.Sc. in Geological Engineering (Mineral Exploration) from Queen’s University in Canada.

David Smith is the Vice President, Exploration of Arizona Metals. He has 30 years of global precious metals exploration experience, including codiscovery of the Solidaridad/La Sabila deposit in Mexico with deposits estimated at 1 million ounces of gold. His core areas of expertise are managing mineral projects from acquisition to exploration, resource modeling and mineral project development. He holds an M.Sc. from the University of Oregon and an MBA from Pinchot University/Presidio Graduate School.

Paul Reid is the Executive Chairman of Arizona Metals. He previously founded and served as Executive Chairman of Telegraph Gold (listed as Castle Mountain Mining), which was acquired by Equinox Gold, a TSX-listed mining company. Paul has extensive experience as an Investment Banking professional, involved in raising capital, go-public transactions, and advisory services.

Arizona Metals Corp. (OTCQX: AZMCF), closed Wednesday's trading session at $2.15, up 3.8647%, on 57,544 volume. The average volume for the last 3 months is 88,784 and the stock's 52-week low/high is $2.00/$3.83.

Recent News

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced that its groundbreaking research utilizing its patented DehydraTECH(TM)-processed cannabidiol ("DehydraTECH-CBD") has been published in eight peer-reviewed articles across six different publications. "The most recent publication in June 2023 in the peer-reviewed International Journal of Molecular Sciences is ‘Differences in Plasma Cannabidiol Concentrations in Women and Men: A Randomized, Placebo-Controlled, Crossover Study.' The addition of this research article builds on the growing body of peer-reviewed literature developed by Lexaria's leading research team into the effects of DehydraTECH-CBD and human health," a recent article reads. "We're proud of the impressive amount of research that our company has been able to develop through its HYPER-H21 series of clinical studies that has now been assessed by a variety of our respected peers," John Docherty, president of Lexaria, is quoted as saying. "Lexaria is establishing itself as one of the world's leaders in the investigation of cannabidiol for the purposes of controlling human blood pressure, and we are now focused on launching an FDA-registered IND program to formally investigate DehydraTECH-CBD for hypertension this year."

To view the full article, visit

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has also collaborated with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has been granted patent protection for specific delivery of nicotine, vitamins, NSAIDs, antiviral drugs, cannabinoids and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Wednesday's trading session at $1.1052, up 3.2897%, on 88,784 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $3.83/$.

Recent News

Canada Nickel Company Inc. (TSX.V: CNC) (OTCQX: CNIKF)

The QualityStocks Daily Newsletter would like to spotlight Canada Nickel Company Inc. (TSX.V: CNC) (OTCQX: CNIKF).

Canada Nickel (TSX.V: CNC) (OTCQX: CNIKF), a company that is advancing the next generation of nickel-sulphide projects, is releasing additional test results from its Mann Northwest Property. The results include drilling from three more holes as well as assay results from the first five holes drilled. Highlights of the report include that the eight holes drilled intersected multihundred-meter intervals of mineralized peridotite and minor dunite across combined strike length of 2.7 kilometers with the target remaining open in all directions. The report also noted that the target geophysical footprint, which is 6 km2, is more than triple the size of the footprint of CNIKF's Crawford project. In addition, the drilling showed that hole MAN23-02 returned 0.26% Ni over core length of 210 meters including 0.31% nickel over 33 meters with the hole ending with 0.52 g/t Pt+Pd over 29 meters.

According to the announcement, the company can potentially earn an 80% interest in the property, where drilling started in the northwest zone. Eight holes have been drilled thus far, with all holes intersecting mineralized sections of predominantly well-serpentinized peridotite and minor dunite. The company also announced that it has agreed to issue a service provider an aggregate of 61,982 common shares at $1.15 per common share to satisfy a $71,280 obligation. The company has also entered into an amending agreement acquire a 100% interest in certain mining claims located in the Province of Ontario. "Our regional exploration program continues to deliver with today's confirmation of another discovery at Mann Northwest, part of Canada Nickel's Timmins Nickel District," said Canada Nickel CEO Mark Selby in the press release. "Mann Northwest has a target footprint more than three timesthat of Crawford and is one of 11 properties with a target footprint larger than Crawford. Three additional holes extended the strike length of mineralization by more than 1,100 meters to 2,650 meters, and assays from first five holes confirmed grades in line with expectations."

To view the full release, visit

Canada Nickel Company Inc. (TSX.V: CNC) (OTCQX: CNIKF) is advancing the next generation of nickel-cobalt sulfide projects to deliver the metals needed to power the electric vehicle (EV) revolution and feed the high growth stainless steel market. The company is one of only a few new sources of potential supply outside Indonesia and China.

Canada Nickel possesses industry leading nickel expertise and is focused on low risk, well established mining jurisdictions. The company has launched wholly owned subsidiary NetZero Metals Inc. to develop zero-carbon production of nickel, cobalt and iron and has applied in multiple jurisdictions to trademark the terms NetZero Nickel, NetZero Cobalt and NetZero Iron. Canada Nickel is also pursuing development of processes to allow net zero carbon production of these elements.

Canada Nickel is currently anchored by its 100% owned flagship Crawford Nickel-Cobalt Sulfide Project with large-scale potential located in the heart of Ontario’s prolific Timmins-Cochrane mining camp, adjacent to major infrastructure.

The company believes the EV industry and many other consumer sectors have an urgent need for zero-carbon metal this decade, not in 20-25 years as contemplated by some resource companies. Canada Nickel also believes that nickel supplies from Indonesia and other Pacific island nations, typically controlled by Chinese-owned companies, are not the answer for batteries needed by GM, Ford and the European automakers working to develop and manufacture EV models.

The company is headquartered in Toronto.

Crawford Nickel-Cobalt Sulfide Project

The Crawford Nickel-Cobalt Sulfide Project is the largest sulfide discovery since the early 1970s and contains the fifth-largest nickel sulfide resource in the world, based on Measured & Indicated resources, according to the latest update. The Crawford project is expected to be one of the largest base metal mines in Canada based on results of a Preliminary Economic Assessment. Early projections by Canada Nickel estimate that the project has the potential to produce 50,000 tons of nickel per year. The company is now in the final stages of completing the project’s feasibility study.

The project is projected to produce 2.8 tons of CO2 per ton of nickel equivalent production, which is 89% lower than the industry average of 34 tons of CO2 per ton of nickel equivalent production.

The company is taking significant steps toward developing the Crawford project as a net zero carbon producer. In addition to harnessing the natural ability of the project’s geology to act as a carbon sink through spontaneous reaction of the host rock once exposed to atmospheric conditions called mineral carbonation, Canada Nickel has discovered a new way to enhance carbon capture, termed In Process Tailings (IPT) Carbonation. This act of conditioning the tailings with a concentrated stream of carbon dioxide before deposition has been demonstrated at lab scale to achieve carbon capture at a rate 8-12 times faster than naturally occurring sequestration, achieving more than 60% of the capture that had previously taken six days.

These latest results move the company further toward production of Net Zero Nickel™ and generation of 21 tonnes of CO2 credits per tonne of nickel, which would produce an estimated average of 710,000 tonnes of CO2 credits annually and 18 million total tonnes of CO2 credits over the expected life of mine. IPT Carbonation does not require complex new technologies and major process modifications and could encourage the development of a net zero carbon industrial cluster centered around the Crawford project.

Canada Nickel in January 2023 announced that its latest test work results support the incorporation of carbon capture and storage into the Crawford project. The company believes that utilization of existing process streams should allow IPT to be efficiently engineered and incorporated into the project’s flowsheet, with an integrated feasibility study for the project expected in the second quarter of 2023.

In December 2022, Canada Nickel announced its engagement on Deutsche Bank Securities Inc. (“Deutsche Bank”) and Scotiabank – two of the world’s leading investment banks with a broad base of mining and industrial expertise – as financial advisors for the equity component of the project financing for the Crawford project. In the same release, the company announced the completion of another significant permitting milestone by filing the detailed project description with the Impact Assessment Agency of Canada. Canada Nickel targets receipt of permits by mid-2025, with construction to immediately follow.

Additional Projects

The Reid Nickel Property is located just 16 kilometers southwest of Crawford, or 37 kilometers northwest of Timmins, and contains an ultramafic body with a target geophysical footprint of 3.9 square kilometers. Preliminary assay results from Canada Nickel’s summer/fall drilling program confirm the presence of mineralized dunite, as well as currently undefined higher-grade sections. Partial assay results confirm expected nickel grades. Nickel mineralization in serpentinized dunite was found in all 16 holes drilled to date.

The Sothman Nickel Property is located 70 kilometers south of Timmins. Five drill holes on the eastern half of the target anomaly confirmed the continuation of ultramafic lithologies, primarily peridotite, with moderate to strong serpentinization and variable amounts of mineralization throughout.

The company in December 2022 announced positive drilling results from its ongoing regional exploration campaign at its Reid and Sothman properties. These latest results continue to reinforce the success of Canada Nickel’s geophysical targeting approach and increase the probability of success at the company’s other 20-plus properties within its 42 square kilometers of geophysical targets.

Building on this momentum, Canada Nickel in December 2022 announced its entry into a deal to acquire a 100% interest in the past producing Texmont property situated between the company’s properties south of Timmins. As noted in the news release, the acquisition of the Texmont property provides near-term smaller scale production potential and is highly complementary to the company’s large-scale Crawford and regional nickel sulphide projects.

Market Opportunity

Global demand leaves the market fundamentally short of nickel in the medium- and long-term. Global primary nickel demand will likely reach 3 million tons in 2022, up from 2.4 million tons in 2020, according to the International Nickel Study Group (INSG).

The INSG says primary nickel production is forecast to hit 3.1 million tons in 2022. Indonesia, the world’s largest nickel miner, halted exports of unprocessed nickel ore in January 2020, due to a government-imposed ban. Indonesia has floated the concept of a nickel cartel whose member nations would exert influence over world nickel supply and prices, similar to OPEC’s pricing power over oil.

Benchmark Minerals, a leading EV supply chain research firm, projects that, by 2035, world demand for nickel will double from current levels to 6 million tons annually. That growing demand represents a need for new nickel production equivalent to 70 mines the size of Canada Nickel’s Crawford Project.

Management Team

Mark Selby is Chairman, CEO and Director of Canada Nickel. He was formerly President and CEO of RNC Minerals, where he led a team that successfully raised over $100 million and advanced the Dumont nickel-cobalt project from initial resource to a fully permitted, construction-ready project. He has held senior management roles with Quadra Mining, Inco and Purolator Courier, and was a partner at Mercer Management Consulting. Since 2001, he has been recognized as one of the leading authorities on the nickel market. He graduated from Queen’s University with a Bachelor of Commerce.

Wendy Kaufman is CFO of Canada Nickel. She has 25 years of experience leading publicly listed mining companies in project financing, capital structuring, capital markets, accounting and internal controls, tax, and financial reporting and public disclosure. She was also previously CFO at Khiron Life Sciences Corp. and held CFO and senior finance positions at Pasinex Resources Limited, Primero Mining Corporation and Inmet Mining Corporation. She holds a Bachelor of Business Administration from Wilfrid Laurier University and is a Chartered Professional Accountant.

Steve Balch is VP Exploration at Canada Nickel. He is an Ontario registered geoscientist with 32 years of experience in geophysics, specializing in magnetic and electromagnetic methods. He founded Triumph Instruments and developed the AirTEM system, a multi-coil helicopter-borne EM system that is in use worldwide. He has also been active in borehole geophysics and helped develop new technologies including north-seeking gyros, temperature compensated induction conductivity probes, UAV-based magnetometers and high sensitivity magnetic gradiometers.

Christian Brousseau is VP Capital Projects at Canada Nickel. He is a professional engineer (P.Eng) with over 30 years of experience in engineering, design and construction in the Canadian mining industry, including six years as Project Director for the Dumont Project and three years as the Engineering and Construction Manager for Detour Gold. Prior to Detour, he held various construction management positions at Osisko’s Malartic Project and at Goldcorp’s Éléonore Project. He also spent eight years at Falconbridge supervising and managing various capital projects.

Canada Nickel Company Inc. (OTCQX: CNIKF), closed Monday's trading session at $2.05, up 3.0151%, on 73,251 volume with 375 trades. The average volume for the last 3 months is 57,207 and the stock's 52-week low/high is $1.04999995/$5.63000011.

Recent News

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle ("EV") manufacturer, today shared an open letter to its shareholders addressing declining stock values. "The company has received numerous requests to respond to the ongoing decline of our stock. Many of these communications have been addressed to me personally with less than kind, and sometimes threatening statements. As CEO of this company, I take all shareholders' concerns seriously. One of my primary responsibilities is to execute the company's business plan, and as evidenced by multiple prior communications to the public, the company continues to make significant strides in that regard. I will summarize some of those at the end of this statement," writes Mullen CEO and Chairman David Michery.

"I am very disappointed by the performance of our stock. As I have previously publicly stated, I do not believe the trading price of our stock even closely resembles the company's actual value. It is evident that, regardless of meeting significant corporate milestones (i.e., vehicle production completion within projected timelines), stock traders continue to place downward pressure on the stock, causing the price to fall. I previously announced that the company engaged Share Intel and other parties to investigate what I suspect to be unlawful trading practices in our stock. We are assembling all the data received to date and should have something to announce in the coming days. I am extremely frustrated that the hard work of Mullen‘s dedicated team and the significant momentum and successes achieved to date are overshadowed by the unrealistic value attributed to our stock. The company and I have demonstrated our commitment to the success of our initiatives by purchasing its stock through the previously announced Share Buy Back program. I have also personally recently purchased stock, demonstrating my unwavering confidence in our company. I remain committed to executing the company's business plan and using all measures at our disposal to eliminate any unlawful trading practices in our stock."

To view the full press release, visit

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Wednesday's trading session at $0.8, up 68.0672%, on 232,624,267 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.3901/$177.75.

Recent News

Reflex Advanced Materials Corp. (CSE: RFLX) (OTCQB: RFLXF)

The QualityStocks Daily Newsletter would like to spotlight Reflex Advanced Materials Corp. (CSE: RFLX) (OTCQB: RFLXF).

Reflex Advanced Materials (CSE: RFLX) (OTCQB: RFLXF) (FSE: HF2), a mineral exploration company, hosted six members of the United States Geological Survey ("USGS") this month at its Ruby Graphite project. The company announced that the USGS visitors were there to verify historical data related to the past-producing mine located within RFLX's Ruby Graphite Project; the mine was operated by the Crystal Graphite Company in the 1940s. According to the announcement, the USGS officials reviewed and evaluated existing records and physical infrastructure; they also conducted geological assessments and studied current data to compare it to the historical records to ensure accuracy and reliability. The Montana-based Ruby Graphite project has significant potential as a valuable source of high-purity graphite within the continental United States, and USGS been particularly interested in conducting a comprehensive verification of the historical data because of the project's significance and the potential economic impact. "We were thrilled to welcome the USGS team to our Ruby Graphite project," said Reflex Advanced Materials CEO Paul Gorman in the press release. "Their legitimacy, expertise and thorough evaluation will help validate the historical data and provide further confidence in the project's potential. This site visit represents a significant milestone for us and underscores our commitment to transparency and scientific rigor."

To view the full press release, visit

Reflex Advanced Materials Corp. (CSE: RFLX) (OTCQB: RFLXF) is a strategic minerals company focused on locating and developing economic properties in the strategic metals and advanced materials space. The company aims to improve domestic specialty mineral infrastructure efficiencies to meet surging national demand from North American manufacturers, effectively positioning itself as one of the only North American suppliers of high purity natural graphite for hi-tech applications.

Reflex Advanced Materials is based in Vancouver, British Columbia. Its project portfolio includes the Ruby Graphite Deposit in Montana and the ZigZag Lithium Property in Ontario.


Ruby Graphite Project

Located in a mining-friendly jurisdiction in southwest Montana, the Ruby Graphite Deposit is a low cost, rapid re-entry opportunity that produced roughly 2,400 tons of graphite from 1902 to 1948. Reflex Advanced Materials holds mining rights for 755 hectares at the Ruby Graphite Project, with 96 federal lode mining claims. Recent samples assay at 95.8% to 98.4% total carbon.

The site is notable as the only combined U.S. graphite flake and vein graphite source. Vein graphite is ideal for energy storage applications, because it requires fewer steps to achieve purity than synthetic alternatives and is therefore far less environmentally damaging. This is expected to play a key role in the project’s development as demand for electric vehicles continues to surge.

In March 2023, the company announced its submittal of permit applications to the Bureau of Land Management in respect of its exploration of the Ruby Graphite Project. Its initial drill program, expected to take place in the summer of 2023, includes plans for 3,500 total meters of drilling, cored to an average depth of 130 meters. The targets for this drill program have been identified using historical data from original mine operations and data gathered for the initial 43-101 technical report on the project, dated January 31, 2023.

ZigZag Lithium Property

Located in the Thunder Bay Mining Division of Ontario, the ZigZag Lithium Property consists of eight mining claims spanning roughly 2,710 hectares. Mineralization at the property, most notably lithium, is based in pegmatite dikes and concentrated in spodumene crystals, which are consistent throughout the entire unit.

Spodumene is readily observable in outcrops and in drill cores, with crystal sizes ranging from 3-15cm, on average.

Reflex Advanced Materials and American Energy Technologies Company Metallurgical Partnership

Reflex Advanced Materials has entered into a material processing agreement with American Energy Technologies Co., which is based in Arlington Heights, Illinois, to conduct metallurgical testwork with the goal of creating a technical support data package for Reflex’s target customer base, U.S. Federal agencies and qualification programs with hi-tech customers in the battery and battery storage business.

The resulting coated, spherionized, purified graphite (CSPG) material that is expected to be created from the aforementioned tests will be used to provide potential customers of CSPG with samples so that they can begin the material qualification process.

Market Opportunity

Graphite is an ideal battery anode and has dominated the market since the proliferation of lithium-ion batteries. Despite this demand, there is currently no significant production of lithium-ion battery anode material in North America.

Instead, most graphite sold in North America today is sourced from Chinese producers. U.S. President Joe Biden highlighted this sourcing disparity in a 2022 address:

“The United Stated depends on unreliable foreign sources for many of the strategic and critical materials necessary for the clean energy transition – such as lithium, nickel, cobalt, graphite and manganese for large-capacity batteries,” he said. “Demand for such materials is projected to increase exponentially as the world transitions to a clean energy economy.”

The U.S. Department of Energy is in the process of awarding $2.8 billion to expand domestic manufacturing of batteries for electric vehicles and combat this foreign dependency. Reflex Advanced Materials has identified its Ruby Graphite Project as a prime candidate for U.S.-sponsored initiatives due to the rarity and scarcity of natural graphite deposits in the country.

Processing graphite domestically in the U.S. is expected to provide Reflex Advanced Materials a competitive advantage as manufacturers begin to seek out American supply in the face of increased diplomatic tension. This is critical, as a rise in anode demand is expected to fuel a shortage of 8 million tonnes of graphite by 2040. World Bank Group projects 494% growth in total graphite demand by 2050.

Leadership Team

Paul Gorman is the CEO and a Director of Reflex Advanced Materials. He brings to the company over 25 years of experience in junior mining finance, public listings, viability assessment and operational rationalization. For 18 years, Mr. Gorman served as president and managing partner of Riverbank Capital, where he played an instrumental role in raising more than $85 million for small-cap companies. In 2008, he funded Industrial Minerals Inc. (later Northern Graphite) and served in an advisory role for four other graphite companies, contributing significantly to the revitalization of the junior graphite space in North America. Mr. Gorman founded Mega Graphite Inc. in 2009 and has served as chief executive for three other companies.

Tasheel Jeerh, CPA, is the company’s CFO. He is a finance and accounting professional with over a decade of experience spanning both public and private sectors. Prior to joining Reflex Advanced Materials, Mr. Jeerh played a pivotal role in the growth of a private upstream oil and gas firm, dealing with over $2 billion in M&A activity and $1 billion in financing activities. He gained his designation at PricewaterhouseCoopers, where he worked as a manager in the assurance practice.

Greg Bell is Project Manager for Reflex Advanced Materials. He is a multi-disciplined engineering management professional with more than 40 years of experience in the natural resources sector. Mr. Bell has successfully built and managed several start-up operations in various capacities. He has been active in graphite and lithium exploration for the past seven years.

Christopher W. Hill leads the company’s Corporate Development initiatives. He is an investor and entrepreneur with over a decade of experience in the capital markets. Mr. Hill began his career as an investment advisor and then began to consult and advise private companies on their paths to becoming publicly traded. He specializes in corporate development and strategic financing utilizing his large network in the capital markets.

Reflex Advanced Materials Corp. (RFLXF), closed Wednesday's trading session at $0.23, up 17.9487%, on 163,810 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.15/$0.765.

Recent News

RVL Pharmaceuticals plc (NASDAQ: RVLP)

The QualityStocks Daily Newsletter would like to spotlight RVL Pharmaceuticals plc (NASDAQ: RVLP).

For the quarter ended June 30, 2023, RVLP reported net sales of $8.3 million and operating expenses of $14.4 million, down 2% and 32%, respectively, compared to the prior year period; this strategy is designed to extend cash runway for future business development and changes in the company's marketing mix

The company's marketing partner, Santen, has commenced the required registrational trial for UPNEEQ(R) in Japan and plans to begin the same in China in 2023

UPNEEQ(R) has strong U.S. intellectual property protection, with patents extending to 2039

RVL Pharmaceuticals launched its prescription ecommerce platform, Elevate, in July 2023, allowing providers and patients to purchase RVL products and sign up for auto-refills

UPNEEQ(R) consumer awareness remains very low among U.S. adult women, presenting a major opportunity to increase awareness and demand through Direct-to-Consumer efforts

RVL Pharmaceuticals plc (NASDAQ: RVLP) is a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, which is available by prescription for the treatment of acquired blepharoptosis, or low-lying eyelid(s), in adults.

UPNEEQ® (RVL-1201) is the first non-surgical treatment option approved by the U.S. Food and Drug Administration (FDA) for acquired blepharoptosis. The company received FDA approval in July 2020 and launched UPNEEQ® in September 2020 to a limited number of eye care professionals, with commercial operations expanded in 2021 among ophthalmology, optometry, and oculoplastic specialties.

In February 2022, UPNEEQ® was launched into the medical aesthetics market in the United States. Patients can purchase UPNEEQ® from eye care or medical aesthetic professionals, or through RVL Pharmacy LLC, the company’s wholly owned pharmacy. The company plans to promote UPNEEQ® to people with acquired ptosis and those who are bothered by low-lying lids. RVL Pharmaceuticals believes there is a significant commercial opportunity for UPNEEQ®, given the meaningful unmet need for a non-invasive treatment across millions of acquired-ptosis patients in the United States. The company’s near-term focus is to continue the rollout of UPNEEQ® into the medical aesthetics market through its dedicated aesthetics sales force while continuing to support ongoing utilization and expanded penetration of UPNEEQ® in ocular medicine markets.

RVL Pharmaceuticals continues to raise patient and physician awareness of acquired ptosis and UPNEEQ® through medical conferences, HCP and DTC advertising, social media (e.g., Facebook and Instagram), and marketing partnerships.

The company is incorporated in Ireland and headquartered in Bridgewater, New Jersey.


UPNEEQ® is an oxymetazoline hydrochloride ophthalmic solution for the treatment of acquired blepharoptosis, or low-lying eyelid(s), in adults. It is the first and only FDA-approved ophthalmic solution for this indication.

The once-daily UPNEEQ® eye drop has been shown in clinical trials to result in an average one-millimeter lift of the upper eyelid, and to improve superior visual field in patients with a functional deficit. Patients’ eyelids demonstrate lift in as little as five minutes post dose, with the lift effect lasting as long as eight hours. The preservative-free solution is safe and well-tolerated. Trials demonstrated side effects similar to those of placebo.

The active ingredient in UPNEEQ® is oxymetazoline 0.1%, a direct-acting α-adrenergic receptor agonist that targets receptors in the Müller’s muscle, which causes the muscle to contract and lift the upper eyelid. UPNEEQ® delivers eye-opening results for patients along the entire spectrum of age and condition severity.

UPNEEQ’s health care provider customers include optometrists, ophthalmologists, oculoplastic surgeons, facial plastic surgeons, dermatologists and a broad range of practitioners qualified to diagnose and treat acquired blepharoptosis in adults.

The target patient population comprises adults with droopy or low-lying eyelids, the majority of whom are female. While the exact prevalence of acquired ptosis is unknown, RVL Pharmaceuticals believes it to be a common age-related condition.

Market Opportunity

A survey of eye care providers and medical aesthetics specialists revealed that they believe that approximately half of adult patients visiting their practices are affected by droopy or low-lying eyelids. Further, the company estimates that approximately 60% of adult women self-identify as having some degree of droopy or low-lying eyelids, and a majority of those women indicate that they are bothered by the position of their eyelids.

The global medical aesthetics market is expected to reach a value of $18 billion in 2027, rising at a compound annual growth rate of over 10%, with North America representing the largest share of the global market. Similarly, the global eye care market is expected to reach a value of $86 billion by 2026, rising at a compound annual growth rate of over 6%. An estimated 100 million adults visit an eye care provider each year in the United States alone.

RVL Pharmaceuticals believes the growth in medical aesthetics and eye care markets will be driven by an aging population and increasing life expectancy, which is resulting in more consumers with a desire for improved appearance and well-being over a longer period of time. Other contributing factors include rising disposable income globally and in the U.S.; growing awareness, utilization, and acceptance of elective or minimally invasive and non-invasive interventions; and continued innovation and improved accessibility to treatments due to an increase in the number of physicians who offer eye care and medical aesthetics services.

Management Team

Brian Markison is Chairman of the Board and Chief Executive Officer of RVL Pharmaceuticals. He has more than 30 years of operational, marketing, commercial development, and sales experience with international pharmaceutical companies. He previously served as the President and CEO of Fougera Pharmaceuticals Inc., a specialty pharmaceutical company. Before that he was Chairman and CEO of King Pharmaceuticals Inc. He also held various senior leadership positions at Bristol-Myers Squibb. He received a bachelor’s degree from Iona College.

James Schaub is Executive Vice President and Chief Operating Officer of RVL Pharmaceuticals. Prior to that he served as COO of Trigen Laboratories. He previously was Vice President, M&A of Fougera Pharmaceuticals. Before that he spent five years with King Pharmaceuticals. Mr. Schaub holds a bachelor’s degree in economics from Middlebury College and an M.B.A. from Rutgers Business School.

RVL Pharmaceuticals plc (NASDAQ: RVLP), closed Wednesday's trading session at $0.1641, up 16.8803%, on 6,849,004 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.13/$2.99.

Recent News

Advanced Container Technologies Inc. (OTC: ACTX)

The QualityStocks Daily Newsletter would like to spotlight Advanced Container Technologies Inc. (OTC: ACTX).

Demonstrations rocked the German capital city of Berlin last weekend as hundreds of Germans joined the country's yearly marijuana legalization protests. Held just days before the German country met to discuss the fate of a draft measure that would get rid of Germany's ban on cannabis, several hundred protestors joined the annual Hanfparade (Hemp Parade) and called on the government to legalize cannabis. The rally began at the Berlin Rotes Rathaus (Red town hall) before the protestors walked a route that took them through the Unter den Linden boulevard and to the government district. Held every year since 1997, the Hemp Parade's main goal is to persuade the government to review and liberalize policies on soft drugs such as hashish and marijuana that come from the marijuana plant. Event organizers also support and advocate for expanded access to medical marijuana as well as the use of hemp, a plant in the cannabis family that produces very minimal amounts of the psychoactive compound tetrahydrocannabinol (THC). As more countries consider and implement marijuana legalization measures, many enterprises are likely to mushroom and thrive in the way that companies such as Advanced Container Technologies Inc. (OTC: ACTX) are finding success by doing business with marijuana companies in the U.S.

Advanced Container Technologies Inc. (OTC: ACTX) is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called Grow Pods, along with related equipment and supplies. Additionally, the company designs and sells patented proprietary medical-grade plastic containers, known as the Medtainer®, that store and grind pharmaceuticals, herbs, teas and other solids or liquids.

ACTX is the leading distributor of Grow Pods. With a controlled environment, food and herbs can be grown without pesticides, harmful chemicals or risk of pathogen contamination, and with low energy consumption. Restaurants, grocery stores, non-profits, MSOs and entrepreneurs can use Grow Pods to ensure a fresh supply of ultra-clean produce year-round.

The company entered the Grow Pod business in October 2020 with its acquisition of all shares of Advanced Container Technologies Inc., a California corporation. As of February 28, 2022, ACTX is exploring the acquisition of the assets and the assumption of some or all of the liabilities of GP Solutions Inc., the developer and manufacturer of Grow Pods, for which ACTX is currently the sole U.S. distributor.

Because Grow Pods can be located almost anywhere, produce can be grown closer to the point of consumption and harvested at its peak, providing nutritious fruits and vegetables where needed. Indoor micro-farms, utilizing a practice known as vertical farming, have attracted the attention of governments and universities, which are now promoting vertical farming as a way to combat food insecurity and inequities.

The United States Department of Agriculture (USDA) has stated that vertical farming “is no longer a futuristic concept.” The department is enthusiastic about vertical farming, particularly those utilizing repurposed shipping containers, such as Grow Pods. Arizona State University reports that vertical farming reduces water use by 90 percent compared to conventional farming but produces 10 times the crop yield.


Grow Pods

One of the company’s main business units is focused on selling advanced, self-contained hydroponic containers called Grow Pods. These unique and innovative automated systems are essentially micro-farms that can be placed virtually anywhere and, with their controlled and specially filtered environment, allow cultivation of a wide variety of crops, 365 days a year. The Grow Pod controlled environment offers major advantages for the production of high-value crops. The ability to grow year-round and the ability to cultivate in a smaller footprint using less water and power are some of the primary advantages of the system. Grow Pods offer constant temperature, humidity and airflow control, as well as automated watering and lighting schedules for optimal growth and minimal labor requirements, regardless of crop.


ACTX meets the needs of the pharmaceutical and medical markets, including the cannabis and hemp industries, with patented packaging systems. The company designs, customizes, brands and sells proprietary medical grade plastic containers that can store pharmaceuticals, herbs, teas and other solids or liquids, with a special built-in feature that can grind solids and shred herbs. The company’s flagship container product is the patented Medtainer®, a child resistant, medical-grade herb container and grinder that is water-tight, air-tight and smell proof. Packaging in the cannabis industry is critical, with numerous stringent regulations about how cannabis products must be packaged and labeled. ACTX also offers custom-branded, compliant vacuum seal bags and other retail container solutions.

Equipment and Supplies

ACTX markets and sells two principal products: Grow Pods, which are specially modified insulated shipping containers manufactured by GP Solutions Inc., in which plants, herbs and spices may be grown hydroponically in a controlled environment, and Medtainers®, which may be used to store pharmaceuticals, herbs, teas and other solids or liquids and can grind solids and shred herbs. The company also markets and sells various products related to Grow Pods and the Medtainer®, as well as providing private labeling and branding services for purchasers of Medtainers® and certain related products.

GP Solutions manufactures and sells other products, such as humidity controllers and LED lighting systems for vertical farming. The company’s specially designed lighting panels are programmed to emit the exact wavelength of light that each crop requires. The system has a daybreak-to-nightfall feature that gives plants the proper chromatic signals to grow rapidly and fruitfully. High efficiency LED light strips supply the crops with a red and blue light spectrum required for photosynthesis in the spectrum that plants need most.

Market Overview

The global vertical farming market is expected to reach $33.02 billion by 2030, according to a new report by Grand View Research. The market is forecast to expand at a CAGR of 25.5 percent from 2022 to 2030, according to Grand View. Escalating production of biopharmaceutical products, including cannabis, is anticipated to drive the market. The building-based segment of the market is expected to register a significant CAGR of 27.8 percent over the projected period. In addition, the climate control segment is expected to see high growth.

The global cannabis packaging market is expected to reach $14.34 billion by 2028, according to analysis by Reports and Data. The analysis forecasts 1,700 percent growth in cannabis users by the end of 2026, with packaging likely observing a whopping 26.42 percent growth in the forecast period. There are significant barriers to entry in the cannabis packaging market, giving an advantage to companies already established in the sector. These barriers include developing a thorough knowledge of the myriad regulations that govern cannabis packaging (which differ in each state), and child-resistance requirements.

Management Team

Douglas P. Heldoorn is the Founder and Chairman of Advanced Container Technologies Inc. He also holds the positions of President, CEO and COO at the company. Mr. Heldoorn has served on the Board of Directors since its inception in 2013. He has also previously held the position of Executive General Manager at Nissan Motor Corp.

Jeffory A. Carlson is CFO and Treasurer of ACTX. Mr. Carlson has also served as the company’s Corporate Controller since 2014.

Advanced Container Technologies Inc. (OTC: ACTX), closed Wednesday's trading session at $0.21, even for the day. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0141/$0.65.

Recent News

Renovaro BioSciences Inc. (NASDAQ: RENB)

The QualityStocks Daily Newsletter would like to spotlight Renovaro BioSciences Inc. (NASDAQ: RENB) .

Combination of advanced AI machine learning technology and proven immunotherapy technology seen as "future of medicine"

Demonstrated success that both companies have shown with their innovative developments is expected to expand synergistically

Potential applications against variety of cancers

The announcement of a binding and exclusive letter of intent to merge, between two of the most innovative companies in their respective fields, is seen as representing a potentially transformative step in the fight against cancer. Considering Renovaro BioSciences (NASDAQ: RENB), an advanced, pre-clinical biotechnology firm in cell, gene, and immunotherapy, that has already demonstrated significant results with its technology against pancreatic cancer, and GEDi Cube, with an AI, machine learning technology that has validated earlier diagnoses of lung cancer in humans, already expanding to 12 additional cancers, combining the companies is being seen as pointing to the future of medicine. Renovaro BioSciences (NASDAQ: RENB), (formerly NASDAQ: ENOB), announced that it remains confident in submitting an Investigational New Drug Application ("IND") for its innovative Cancer Platform in early/mid 2024 following review of comments made by the U.S. Food and Drug Administration ("FDA") on the company's Pre-IND submission. The company's proprietary, novel technology uses cell- and gene-therapy to promote renewed immune response against solid tumors. "We are grateful to the FDA for the very timely, thorough and clear direction that was provided. After a comprehensive review by our management, scientific, regulatory, and clinical operations teams, we believe we have a clear path forward to submit an IND in early/mid 2024 with clinical trials potentially beginning in first half of 2024," said the company's CEO Dr. Mark Dybul. To view the full press release, visit

Renovaro BioSciences Inc. (NASDAQ: RENB), formerly Enochian BioSciences Inc., is an advanced, pre-clinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy. The company aims to unlock potentially long-term or life-long cancer remission in some of the deadliest cancers, and to potentially treat or cure serious infectious diseases such as Human Immunodeficiency Virus (HIV) and Hepatitis B Virus (HBV) infection.

The oncology platform is now at the forefront of Renovaro’s development activities. While Renovaro’s current efforts focus primarily on pancreatic cancer, it plans to include other solid tumors with short life-expectancy in the first in human Phase I/IIa studies that are on track to start by mid-2024. The company’s Pre-Investigational New Drug (pre-IND) submission included a human study plan covering pancreatic cancer, as well as other cancers that are difficult to treat, potentially including triple-negative breast cancer, head and neck cancers and mesothelioma.

Renovaro’s proprietary, novel technology uses cell- and gene-therapy to promote a renewed immune response against solid tumors. Important confirmatory results from two humanized mouse models using the company’s novel dendritic cell-based therapy, independently conducted by Dr. Anahid Jewett, a renowned cancer researcher in the field of immunotherapy at UCLA, were presented previously at two scientific conferences and were the foundation supporting a pre-IND submission to the U.S. Food and Drug Administration. Notably, Dr. Jewett’s findings from these studies consistently demonstrated 80% to 90% pancreatic tumor reduction in size and weight that was correlated with significant enhancement of key aspects of the immune response.

Renovaro is headquartered in Los Angeles, California.


Renovaro’s product development strategy is anchored in the use of “non-self” or allogeneic cells that enhance targeted immune response. Its lead candidate, RENB-DC11, is an innovative therapeutic vaccination platform that could potentially be used to induce life-long remissions from some of the deadliest solid tumors.
Treatment with RENB-DC11 has now been shown to significantly reduce the size of human pancreatic tumors in humanized mice in three independent studies. The reduction in tumor size correlated with statistically significant increases in key components of an immune response.

Pre-IND was completed in June 2023, with IND filing forecast for first half of 2024. First in-human Phase I/IIa trials are predicted shortly after in H1 of 2024, including pancreatic and other solid tumors with poor treatment options and life-expectancy.

Renovaro believes that RENB-DC11 could represent the most promising and effective strategy to achieve life-long remission for a number of common and deadly tumors.

Other Development Candidates

In addition to its lead oncology platform, Renovaro’s development pipeline includes a platform targeting infectious diseases, including:

  • RENB-HV12 – An engineered allogeneic T-Cell vaccine, this therapeutic HIV vaccine candidate enhances immune infiltration, immune killing and immune surveillance. Potential pre-IND submission is planned for first half of 2024, with IND-submission expected in second half of 2024.
  • RENB-HV21 – Leveraging allogeneic NK plus Gamma Delta T (GDT) cells as potential therapy for HIV, ENOB-HV21 shows promising preliminary results without confounding factors. Renovaro owns an exclusive license and has completed the Pre-IND submission, with a potential IND submission and human trials expected in 2024.
  • RENB-HV01 – Caring Cross, a non-profit corporation, has shown that its proprietary CAR-T cells cure HIV in a mouse model. Studies in humans have begun. Renovaro has entered into a profit-sharing sublicense with Caring Cross and would share in profits if the product is commercialized.
  • RENB-HB01 – This therapeutic approach aims to eliminate all HBV rapidly (“seek and kill”) with a two to three dose treatment regimen. It is expected to be applicable for early disease to maximize impact with low risk of toxicity. Pre-IND comments have been received from the FDA for its AAV-delivery system.
    LOI to Merge with GEDi Cube International Ltd.

On August 9, 2023, Renovaro announced its execution of a binding, exclusive letter of intent to merge a subsidiary with cutting-edge health AI company GEDi Cube International Ltd. The combined company is expected to create a potential multiplier effect to accelerate earlier diagnosis, more effective therapy, and precision in silico drug discovery.

GEDi Cube’s innovative technology, developed over nearly a decade, has already validated earlier diagnoses of lung cancer in humans at a leading university hospital. GEDi Cube has likewise created the early diagnosis technology for 12 additional cancers, including pancreatic and breast cancer.

“I believe joining forces with GEDi Cube could enhance the efficacy of our upcoming trials and speed up the discovery of novel treatment approaches, thereby extending our life-saving technology to more cancer patients and renewing hope for them and their families,” Dr. Mark Dybul, CEO of Renovaro, stated in the news release.

GEDi Cube is led by CEO Craig Rhodes, who brings to that company tremendous industry experience leading life sciences groups at industry leaders Intel, Oracle and NVIDIA.

Market Opportunity

Pancreatic cancer alone is diagnosed globally in approximately 495,000 people each year, including roughly 64,000 in the U.S. Nearly 466,000 of those patients die annually, including approximately 51,000 in the U.S. Because of limited treatment options, life expectancy is very poor – with an approximately 10% patient survival rate at five years after diagnosis.

The global pancreatic cancer treatment market was valued at $2.15 billion in 2021 and is projected to grow from $2.48 billion in 2022 to $6.85 billion by 2029, according to Fortune Business Insights. That growth represents a CAGR of 15.7% for the forecast period.

A separate report from Fortune Business Insights projects that the global HIV drug market will grow from $30.46 billion in 2021 to $45.58 billion in 2028, recording a CAGR of 5.9% over the forecast period.

According to GlobalData, the value of the market for hepatitis B treatment is forecast to experience a significant increase in the coming years, with revenues expected to grow from $1.6 billion in 2022 to $10.5 billion in 2029. That represents a very rapid CAGR of 30% over the period. An estimated 296 million people suffer from the condition worldwide.

Management Team

Dr. Mark Dybul is the CEO of Renovaro. He has served as a tenured professor in the Department of Medicine at Georgetown University Medical Center since June 2017. He also served as Faculty Co-Director of the Center for Global Health and Quality from 2017-2021. Dr. Dybul has worked on HIV and public health for nearly 30 years as a clinician, scientist, teacher and administrator, including as an architect and eventually the Global Ambassador of the U.S. President’s Emergency Plan for AIDS Relief and the Executive Director of the Global Fund to Fight AIDS, Tuberculosis and Malaria from 2013 through May of 2017, and as the co-director of the Global Health Law Program at the O’Neill Institute for National and Global Health Law from 2009 through 2012. He is a member of the U.S. National Academy of Medicine.

Luisa Puche is the company’s CFO. She has served as a senior accounting and financial advisor and president of Puche Group LLC from 2015-2019. She served in various key executive roles, including Interim Chief Accounting Officer, at Brightstar Corp., a $10 billion global wireless device services provider. Ms. Puche began her career at Ernst & Young, where she served for approximately 10 years. Leveraging her broad global audit, advisory and corporate expertise, she has provided strong cross-functional leadership experience managing small and large projects for both publicly traded and privately held companies in various industries, including a global implementation of the latest revenue recognition accounting standard for Del Monte, as well as the global implementation of their SOX-404 program.

Francois Binette, Ph.D., is the Chief Operating Officer and Executive Vice President of Research & Development at Renovaro. He has over 25 years of product development expertise in Advanced Therapies and Regenerative Medicine. His broad industry experience spans a wide range of serious medical conditions, from orthopedics to ophthalmology, CNS and immuno-oncology. His career includes positions at Genzyme, Biosyntech, the DePuy Franchise of Johnson and Johnson, Medtronic and Lineage Cell Therapeutics. He received his Ph.D. from Laval University in Québec, followed by post-doctoral training at the Sanford-Burnham Institute in La Jolla and Harvard Medical School in Boston.

Renovaro BioSciences Inc. (NASDAQ: RENB), closed Wednesday's trading session at $2, off by 6.9767%, on 255,617 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.3928/$2.74.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

Canadian researchers have developed a powerful imaging technique that would aid physicians in their fight against cancer. The team from the School of Biomedical Engineering at Dalhousie University in Canada has designed a high-resolution endoscopic surgical and imaging probe, the very first in the world capable of allowing surgeons to see brain tumors in 10 times more resolution than traditional imaging technologies such as CT and MRI scans. Brain cancers are among the most debilitating types of cancer, affecting tens of thousands of Americans each year, and are forecast to take close to 20,000 lives in 2023. Tumors of the brain and spinal cord are especially hard to treat and have low survival rates because their proximity to the brain makes them incredibly difficult to treat via means such as radiation and surgery without damaging healthy brain tissue. Furthermore, natural defenses such as the blood-brain barrier, which are designed to protect the brain from dangerous substances, prevent drugs from reaching brain tumors and reduce the effectiveness of brain-tumor treatments. As brain cancer surgery improves, the drugs developed by enterprises such as CNS Pharmaceuticals Inc. (NASDAQ: CNSP) can boost cancer treatment by killing off any remaining cancer cells that aren't removed during the surgical procedures.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Wednesday's trading session at $1.71, off by 1.7241%, on 335,598 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.6105/$8.64.

Recent News

Prospera Energy Inc. (TSX.V: PEI) (FRA: OF6B) (OTC: GXRFF)

The QualityStocks Daily Newsletter would like to spotlight Prospera Energy Inc. (TSX.V: PEI) (OTC: GXRFF) .

Prospera Energy (TSX.V: PEI) (OTC: GXRFF) (FRA: OF6B), a public oil and gas exploration, exploitation and development company focusing on conventional oil and gas reservoirs in western Canada, has selected IBN (InvestorBrandNetwork) as its corporate communications partner. A multifaceted financial news and publishing company for private and public entities, IBN will leverage its investor-based distribution network of more than 5,000 key syndication outlets, various newsletters, social media channels, wire services via InvestorWire, blogs and other outreach tools to generate greater awareness for Prospera Energy. Prospera Energy develops, acquires and drill assets with potential for primary and secondary recovery with a primary focus on optimizing hydrocarbon recovery from legacy fields using environmentally safe and efficient reservoir development methods and production practices. The company is undergoing a three-stage restructuring process designed to prioritize cost-effective operations while appreciating production capacity and reducing liabilities.

The company's core properties include more than 42,000 cumulative acres across Cuthbert, Luseland and Heart Hills in Saskatchewan and Red Earth and Pouce Coupe in Alberta. "Since enacting its top-down reorganization in 2021, Prospera has achieved tremendous growth," said IBN director of operations Chris Johnson in the press release. "In May 2023, the company reported a threefold year-over-year increase in annual revenue for 2022 alongside drastically reduced operating costs and record-high cash flow from operations. We're excited to customize our comprehensive suite of corporate communications solutions for Prospera, which is positioned to execute the second phase of its development plan, aimed at increasing production through medium-oil development in Alberta and leveraging horizontal wells to capture the significant remaining reserves in Saskatchewan."

To view the full press release, visit

Prospera Energy Inc. (TSX.V: PEI) (OTC: GXRFF) (FRA: OF6B) is a public oil and gas exploration, exploitation and development company focusing on conventional oil and gas reservoirs in Western Canada. The company uses its experience to develop, acquire and drill assets with potential for primary and secondary recovery.

Prospera is primarily focused on optimizing hydrocarbon recovery from legacy fields through environmentally safe and efficient reservoir development methods and production practices. It is in the midst of a three-stage restructuring process aimed at prioritizing cost effective operations while appreciating production capacity and reducing liabilities.

The company is based in Calgary, Alberta, Canada.


Prospera’s core properties include more than 42,000 cumulative acres across Cuthbert, Luseland and Heart Hills in Saskatchewan and Red Earth and Pouce Coupe in Alberta. In total, the company estimates that there are half a billion barrels of oil in place at these sites accounting for 20+ years of forward project lifespan, with as little as 8% of total reserves having been recovered via legacy vertical well technology.

Restructuring Initiative

In 2021, Prospera enacted a top-down reorganization. The early results of these efforts were on display in May 2023, when the company reported a three-fold year-over-year increase in annual revenue for 2022 alongside drastically reduced operating costs and record-high cash flow from operations.

Prospera noted in the news release that it has positioned itself in 2023 to execute the second phase of its development plan aimed at increasing production through medium-oil development in Alberta and leveraging horizontal wells to capture the significant remaining reserves in Saskatchewan.

During the company’s investor summit in August 2023, Prospera CEO Samuel David provided more information regarding this three-phase strategy:

Phase I

Prospera completed the first phase of its restructuring by optimizing operations at its existing assets and addressing legacy arrears and non-compliance issues.

At the beginning of this transformation, the company was producing just 80 barrels of oil equivalent (BOE) per day. In Q4 of last year, Prospera peaked at nearly 1,200 BOE per day. Its breakeven is around 500 barrels per day, illustrating the opportunity for free cash flow. This prospect has driven Prospera’s capital development and optimization in recent quarters.

After a temporary slowdown in production due to harsh winter conditions, Prospera is currently producing about 800 BOE per day and anticipates an additional 300-500 barrels of daily production following the completion of ongoing site maintenance work.

This sustained increase has pushed the company’s NPV from roughly $3 million prior to the restructuring efforts to approximately $72 million today.

In an effort to build on this progress and maximize its available resources, Prospera piloted two horizontal reentries to assess a potential horizontal well transformation at its properties.

Phase II

Following up on the optimization efforts of Phase I, Prospera aims to commence a horizontal well transformation at its properties in the coming months. Based on its pilot wells from Phase I, the company has proposed 10 horizontal well locations at its Cuthbert and Heart Hills properties.

Prospera has likewise proposed eight medium light oil direction wells at its Alberta property, and it is exploring strategic acquisitions aimed at expanding its core area and diversifying its product mix.

Other facets of Phase II include piloting an enhanced oil recovery (EOR) application and continuing to execute its liability management goals and ESG initiatives. Prospera has already abandoned 60 vertical wells as part of its three-year LMR plan to reclaim surface land and reduce the environmental footprint of its operations.

Phase III

Beginning next year, Phase III of Prospera’s corporate redevelopment strategy will focus on continuing the company’s horizontal modular development to appreciate production and optimize recovery of remaining reserves. Prospera intends to implement full-scale EOR applications based on the results of its Phase II pilot program, which is forecast to optimize recovery by greater than 10%.

Prospera also intends to continue its acquisition strategy to diversify its product mix. Its goal, as detailed by in August 2023 investor summit, is to attain 50% light oil, 40% heavy oil and 10% gas – all while continuing to eliminate carbon emissions as part of its existing ESG initiatives.

Poised for Growth

Following its transformational efforts in 2022, Prospera is poised to achieve record growth in 2023. The company has forecast significant reductions in production costs through 2024, alongside sizable increases in daily production.

Prospera is currently exploring strategic acquisition targets to potentially increase its production beyond 5,000 BPD while expanding its reserve base to a billion barrels.

Market Opportunity

While the oil and gas industry faces long-term geopolitical and macroeconomic uncertainty, there is a clear trend to secure supply in the short term. According to Deloitte, the global upstream industry ended 2022 with some of the highest free cash flows on record, driving reinvestment in hydrocarbons and overall investment in clean energy.

The Energy Information Administration recently forecast a dip in global oil inventories over each of the next five quarters, placing upward pressure on oil prices. The agency further forecasts a YoY increase in fuel consumption, exacerbating the effects of OPEC+ production cuts that are set to remain in place through 2024.

For Prospera, these forecasts are promising. The company aims to build on its recent financial growth in the coming months (Prospera reported a three-fold YoY increase in revenue to $13.9 million in 2022), hitting a projected $57 million in total revenue by the end of 2024 while working to expand its core area holdings through accretive M&A transactions.

Leadership Team

Prospera is led by a team with extensive, diverse petroleum industry experience spanning both reservoir management and operations of oil and gas assets. The team boasts a proven track record of reorganizing companies, structuring financing arrangements and positioning for growth.

Samuel David is the company’s President and CEO. He brings to Prospera over 32 years of experience in operation, development and management of oil and gas assets and companies. Mr. David holds a B.Sc. in Mechanical Engineering and a B.A. in Economics from the University of Calgary. His background consists of both engineering and executive management experience with majors Petro-Canada, AEC Oil & Gas (now EnCana / Cenovus) and Husky Energy, as well as founding and operating juniors Ventura Energy and First West Petroleum. Mr. David has proven expertise in corporate planning, production, reservoir engineering, depletion strategies, EOR, property evaluations, acquisitions and divestitures.

George Magarian is VP Subsurface for Prospera. He is a professional petroleum geologist (APEGA) with over 36 years’ experience in the Western Canada Sedimentary Basin. After graduating with an Honors B.Sc. degree in Earth Science from the University of Waterloo, Mr. Magarian spearheaded many successful exploration programs, conducted evaluations for improved recovery schemes and assessed/exploited unconventional oil reservoir opportunities. He has held roles of increasing responsibility, from exploration geologist at oil industry major Petro-Canada and intermediates Anderson Exploration and Jordan Petroleum, to geoscience manager and VP exploration at junior companies Ionic Energy, Gentry Resources and Westfire Energy.

Chris Ludtke is the company’s VP Finance & Accounting. He is a high functioning finance leader with extensive expertise in finance, budgets and planning, accounting, economic evaluation, management, governance and sound decision making. Mr. Ludtke has 20 years of experience within the oil and gas, clean energy and renewables industries, including 12+ years working for Husky Energy before moving into an executive role in the junior oil and gas and hydrogen space. He graduated from the University of Lethbridge (Bachelor of Management) and is a Chartered Professional Accountant in the Province of Alberta.

Matthew Kenna is the CFO of Prospera. He has over 30 years’ experience leading organizations and helping them expand, drive efficiencies and grow profitability. Mr. Kenna is a professional accountant (CPA, CMA) and spent 15 years heading up the financial and operating departments at KUDU Industries, where he fostered financing arrangements, client relationships and manufacturing teams to take the organization from $35M to $150M in revenue. He has extensive experience turning companies around, growing them and building efficient organizations.

Prospera Energy Inc. (OTC: GXRFF), closed Wednesday's trading session at $0.083, off by 2.2379%, on 90,300 volume. The average volume for the last 3 months is 90,300 and the stock's 52-week low/high is $0.0352/$0.134.

Recent News

First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF)

The QualityStocks Daily Newsletter would like to spotlight First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF) .

First Tellurium (CSE: FTEL) (OTCQB: FSTTF) recently uplisted to the OTCQB venture market, reflecting its growth and commitment to explore for – and provide – green and critical metals. "The move was approved by the OTC Markets Group in June, and First Tellurium has been trading on the OTCQB under the symbol FSTTF ever since. The uplisting has drawn increased focus and credibility to the company's two flagship projects: the Colorado-based Klondike tellurium-gold project and the British Columbia-based Deer Horn tellurium-gold-silver-copper project. These two projects are key to First Tellurium's commitment to supply critical and essential metals, including tellurium, for North American markets," explains a recent article. "Upgrading our OTC market listing has been an important, long-term goal of the company," First Tellurium CEO and President Tyrone Docherty is quoted as saying. "This milestone gives us far greater access and exposure to the crucial U.S. investment market, allowing us to attract a larger shareholder audience. The OTCQB is recognized as an established public market by the Securities and Exchange Commission, and it offers investors transparent, high-quality trading."

To view the full article, visit

First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF) is committed to exploring for and providing essential and critical metals, including tellurium, gold, silver, copper and tungsten, for North American markets. This objective is anchored by the company’s Deer Horn tellurium-gold-silver-copper project in British Columbia, Canada, and further enhanced by its property option on the Klondike tellurium-gold prospect located in Colorado, USA.

First Tellurium’s unique business model is to generate revenue and value through mineral discovery, project development, project generation and cooperative access to untapped mineral regions in indigenous territory with sustainable exploration potential.

Through its exploration and partnerships with Fenix Advanced Materials, Cheona Metals and IRMA, First Tellurium strives to generate a measurable, beneficial social or environmental impact alongside a financial return. The company conducts a diversified search for metals, working in alliance with indigenous peoples, NGOs, governments and leading metals buyers. First Tellurium believes this is the future of mineral exploration — generating revenue by exploring responsibly and leveraging diverse partnerships.

First Tellurium proudly adheres to, and supports, the principles and rights set out in the United Nations Declaration on the Rights of Indigenous Peoples and, in particular, the fundamental proposition of free, prior and informed consent.

The company is headquartered in Vancouver, British Columbia.


Deer Horn Tellurium-Gold-Silver-Copper Project

Deer Horn is located on 51.33 square kilometers (km) in west-central British Columbia, 36 km south of the prolific Huckleberry copper-molybdenum mine and 135 km southwest of the community of Burns Lake. It is one of few significant tellurium discoveries outside Asia and includes a 2.4 km-long vein system of high-grade gold, silver and tellurium, as well as broader zones of bulk-tonnage gold, silver and tellurium mineralization. The company completed a positive Preliminary Economic Estimate and has began permitting for a 10,000-tonne bulk sample program to advance the project toward mine feasibility. It is North America’s only silver-gold-tellurium property with an NI 43-101 compliant tellurium resource, and it hosts a number of other mineralized targets and zone containing critical metals such as copper, tungsten and zinc.

First Tellurium owns 50% of the property, with an option to acquire up to a 75% interest. The company has engaged Dias Geophysical of Saskatoon, Saskatchewan, to conduct induced polarization (IP) geophysics on the Deer Horn Project in summer 2023. The program is designed to help develop drill targets for a subsequent drilling program.

Klondike Gold-Tellurium Project

The Klondike property is located in Saguache County, Colorado, southwest of Buena Vista in the state’s historical mining district. The company reports it has engaged Burgex Mining Consultants of Sandy, Utah, to stake additional claims around the Klondike property. The claims have been filed with the Bureau of Land Management.

Klondike demonstrates exceptional tellurium grades. Tellurium, used in high-efficiency cadmium telluride (Cd-Te) solar panels, next-generation lithium-ion batteries and thermoelectric devices to change heat into energy, is an essential element for the world’s transition to green energy.

The Klondike property was a top tellurium prospect owned previously by First Solar Inc., one of the world’s largest solar panel producers. First Solar terminated its worldwide raw materials exploration program in 2012 and sold the property to Colorado Klondike LLC, which optioned the project to First Tellurium. Colorado Klondike, led by First Solar’s former Exploration Manager in North America, is managing the upcoming exploration program.

The Colorado Geological Survey (CGS), in partnership with the Colorado School of Mines, reported on First Solar’s exploration at Klondike in 2015, noting: “Surface sampling by First Solar, Inc. in 2006 found very high tellurium grades of up to 3.3% (33,000 ppm), along with locally high gold grades. Tellurium grades at Klondike were the highest encountered in the company’s nationwide exploration program.”

Market Outlook

First Tellurium in spring 2023 referenced recent forecasts by the International Energy Agency (IEA) pointing to rapid growth in solar photovoltaic (solar PV) deployment worldwide. According to the agency, solar PV installations will generate more power by 2027 than any other energy source, including coal, natural gas and hydro. To meet this demand, consumption of both silver and tellurium, key components of solar panels, is expected to surge in coming years.

Chen Lin, founder of Lin Asset Management, has written in his investment newsletter for clients that solar PV is now the largest industrial usage of silver. He said that in 2022 solar PV production used about 12% of total silver demand, or about 120 million ounces of silver. Lin expects this number to rise dramatically in the coming years, and that is likely to lead to silver supply deficits for decades to come.

Lin points out that solar power is now the cheapest source of energy in many parts of the world and that all forecasts point to dramatic expansion of solar PV in the coming two decades. Conservative estimates forecast 300 gigawatts of solar PV production by 2027, up from the current level of about 200 gigawatts.

Management Team

Tyrone Docherty is President, Director and CEO of First Tellurium Corp. He previously served as President and CEO of Quinto Mining Inc. With limited resources in a difficult market environment, he raised more than $30 million and advanced its Quebec iron ore property to a viable project. Quinto later sold for $175 million. From 2012 to 2018, he was Director and Chairman of Mason Graphite Inc. He has worked in the financial and minerals markets for more than 30 years.

Tony Fogarassy, M.Sc. LL.M., is Chairman of First Tellurium Corp. He is a lawyer and a geologist. His extensive legal and technical expertise includes minerals, oil and gas, coal and renewable energy projects and environmental and aboriginal/indigenous law in North America, Africa and Asia. He graduated as gold medalist in geological sciences from the University of British Columbia and in law from the London School of Economics.

First Tellurium Corp. (OTCQB: FSTTF), closed Wednesday's trading session at $0.079, off by 1.3733%, on 7,700 volume. The average volume for the last 3 months is 7,700 and the stock's 52-week low/high is $0.071/$0.1765.

Recent News

Prime Harvest Inc.

The QualityStocks Daily Newsletter would like to spotlight Prime Harvest Inc.

Prime Harvest Inc., based in San Diego, California, is a technology-focused, full-service cannabis company with horizontally diversified operations spanning various segments of the cannabis value chain, from licensing acquisition and compliance management to direct-to-consumer operations. The company is leveraging a long-term strategy of investing in the growth and scale of licensed assets anchored by the power of data-driven technology to expand its footprint throughout California.

Sustainability is key to Prime Harvest’s corporate vision. The company aims to ensure that the communities it serves capture their fair share of the fruits of the industry’s growth, including financial profit, employment opportunities, environmental enrichment and impactful innovation through R&D and education.

The company’s mission is to appeal to the ethos of the cannabis consumer by setting a new operational standard emphasizing accountability, sustainability and community. With this commitment, Prime Harvest continues to work toward positively affecting millions of lives through the creation of a world-class platform that caters to strengthening the commercial cannabis pipeline.

Jaxx Cannabis

Jaxx Cannabis is the flagship brand in Prime Harvest’s portfolio. Through Jaxx Cannabis, the company aims to use technology to facilitate a true customer-centric culture while enhancing the overall craft cannabis experience. Jaxx features an expertly curated selection of premium products from some of the most respected brands in the thriving California market.

Key values serving as the foundation of Jaxx Cannabis include:

  • Creating and nurturing a welcoming culture for all
  • Unlocking the true potential of customer value
  • Being innovative in uncovering new ways to grow both the company and the industry
  • Meeting the wants and needs of consumers to promote profitability
  • Remaining accountable for the results of its operations

It is these values that differentiate Prime Harvest and Jaxx Cannabis in the California cannabis sector.

Brand Partnerships

Prime Harvest works diligently to establish strong alliances with complementary brands that are in alignment with its culture and values. Through a combination of deliberate foresight and strategic action, the company seeks to grow existing cannabis brands and continuously discover new, high-potential performers that are primed for long-term success.

These partnerships enhance Prime Harvest’s efforts to transform the world’s cannabis access and bring its consumers high-quality products that are fair for both people and the planet.


Prime Harvest remains committed to the goal of creating a more sustainable environment, now and in the future. Concern for human beings and the environment can be observed in every facet of its operations, including its ongoing R&D activities dedicated to exploring methods of reducing and repurposing waste into composite materials and exploring the potential of the hemp plant for industrial and wellness contributions.

The company is a proud member of the Community Alliance Program, a foundation that seeks to make a difference in local communities by providing financial assistance for educational programs, housing homeless veterans, creating urban farms, and holding local arts initiatives for children and adults. The program also helps explore the natural healing attributes of medical cannabis through research, development, clinical trials, and advocating for the safe access of cannabis to those in need.

Market Overview

Ongoing changes in U.S. state government policies toward cannabis are expected to cause demand for legal marijuana to surge. In addition, the number of indications for which medical marijuana is prescribed continues to increase. These factors are expected to rapidly boost legal sales of cannabis products.

Legal sales across the U.S. hit a record of $17.5 billion in 2020, marking an increase of 46% over 2019, according to Forbes. This strong growth is expected to continue. According to a Grand View Research report, the global legal marijuana market is forecast to grow at a CAGR of 26.7 percent from 2021 to 2028.

California – Prime Harvest’s home state – has consistently led the pack in terms of U.S. cannabis sales. The Motley Fool pegged cannabis spending in the Golden State at $3.8 billion in 2020, more than doubling the second state on its list.

Leadership Team

The Prime Harvest team is composed of true experts in their respective fields focused on building a world-class organization capable of driving the cannabis industry and movement forward.

E. Duane Alexander is the company’s Founder and CEO. He brings to the team more than 25 years of real-world, hands-on cannabis retail, marketing and commercial operations experience. Mr. Alexander has championed 40+ cannabis license applications throughout the western U.S. to date.

John Wilczak is the COO of Prime Harvest. He has 30+ years of executive management, strategy development & configuration experience with GE, pharmaceutical and agriculture companies. Mr. Wilczak is a Brown & Columbia MBA with vast knowledge of technology driven intellectual properties.

Andrea Jenson is the Chief Financial Officer of Prime Harvest. As CFO, she is responsible for all the company’s financial functions, including accounting, corporate finance and investor relations. Her career spans more than 20 years of varied experience in financial management, business leadership and financial strategy.

John Kazanjian is the VP of Business Development of Prime Harvest. He has worked over 40 years in business operations, brand marketing, sales and investor/lender communications. Mr. Kazanjian earned his B.S. from Rutgers University and his MBA from Harvard University.

Johann Balbuena is the Chief Marketing Officer of Prime Harvest. She has more than six years of experience in California cannabis licensing acquisition and compliance management. Ms. Balbuena has led multimedia production and content marketing efforts for the likes of the Social Club TV app, The Emerald Cup, High Times, Weedmaps and Synergy.

Recent News


The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.